When prostate cancer cells become resistant to strong androgen-receptor blockers, such as enzalutamide, their common characteristics change from slow-growing and noninvasive to fast-growing, highly invasive type, but the knowledge about critical signaling mechanisms driving rapid growth and resistance to enzalutamide is still limited. Here, AR is linked to prostate cancer.